Global clinical trials activity increased by 0.5% in Q3 2020, when compared with the same quarter in 2019, according to GlobalData.
Industry sponsored trials accounted for a 51.4% share of overall activity in Q3 2020, an increase of 7.5% when compared with Q3 2019.
Non-industry sponsored trials accounted for a 48.6% share of all clinical trials in Q3 2020, marking a decrease of 7.5% when compared with the same period in 2019.
Q3 2020 industry sponsored clinical trials activity by therapy areas
Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2020, accounting for a 28.0% share of all trials.
This was followed by infectious disease with a 20.4% share, central nervous system with 12.8%, respiratory with 7.0% and metabolic disorders with 6.9%.
In Q3 2019, oncology led with a 29.0% share, followed by central nervous system with 14.6%, infectious disease with 11.2%, metabolic disorders with 9.0%, and cardiovascular with 8.9%.
|Industry sponsored trials: Q3 2020 vs Q3 2019|
|Therapy Area||Q3 2019||Q3 2020||Activity|
|Central Nervous System||14.6%||12.8%|
|Genito Urinary System And Sex Hormones||3.1%||2.4%|
|Ear Nose Throat Disorders||1.7%||1.1%|
|Mouth and Dental Disorders||0.9%||0.4%|
|Non Malignant Disorders||0.3%||0.1%|
Most active therapy areas in non-industry sponsored clinical trials
In Q3 2020 the leading therapy area for non-industry sponsored clinical trials was oncology, accounting for a 24.8% share of all trials.
This was followed by infectious disease with a 22.5% share, central nervous system with 20.6%, cardiovascular with 8.2%, and respiratory with 6.4%.
In Q3 2019, central nervous system held the lead in non-industry sponsored clinical trials with a 27.9% share, followed by oncology with 19.4%, cardiovascular with 8.6%, infectious disease with 8.1%, and gastrointestinal with 7.2%.
|Non-Industry sponsored trials: Q3 2020 vs Q3 2019|
|Therapy Area||Q3 2019||Q3 2020||Activity|
|Central Nervous System||27.9%||20.6%|
|Genito Urinary System And Sex Hormones||4.2%||3.0%|
|Mouth and Dental Disorders||3.0%||1.8%|
|Ear Nose Throat Disorders||1.6%||0.8%|
|Non Malignant Disorders||0.6%||0.4%|
Asia-Pacific region has the most activity for industry sponsored clinical trials
Asia-Pacific was the most active region for industry sponsored clinical trials activity in Q3 2020 with a 46.2% share, compared with 52.9% in Q3 2019.
North America was the second most active region with a 38.9% share in Q3 2020, up from 31.9% in Q3 2019, followed by Europe with a 29.7% share in Q3 2020, up from 29.6% in Q3 2019.
Single country studies held an 82.7% share in industry sponsored clinical trials in Q3 2020, compared with 83.7% in Q3 2019. Multinational trials accounted for 17.3% in Q3 2020, against 16.3% in Q3 2019.
Regional activity for non-industry sponsored clinical trials
Asia-Pacific saw the most non-industry sponsored clinical trial activity in Q3 2020 with a 41.2% share, down from 53.8% in Q3 2019.
North America held the second position with a 26.1% share in Q3 2020, compared with 18.4% in Q3 2019. This was followed by Middle East and Africa with a 16.1% share in Q3 2020, against 15.9% in Q3 2019.
Single country studies accounted for 98.6% share of non-industry sponsored clinical trials in Q3 2020, compared with 98.8% in Q3 2019. Multinational trials accounted for a 1.4% share in Q3 2020, up from 1.2% in Q3 2019.
Clinical trials by phase in Q3 2020
Phase II trials outnumbered all other studies with a 37.8% share for industry sponsored trials in Q3 2020, compared with 32.5% in Q3 2019.
The share of Phase I trials stood at 33.3% in Q3 2020, down from 38.7% in Q3 2019. Phase III trials increased to 17.1% in Q3 2020, compared with 15.0% in Q3 2019, followed by Phase IV trials with an 11.8% share in Q3 2020, against 13.8% in Q3 2019.
For non-industry sponsored clinical trials, Phase II activity increased to a 47.2% share in Q3 2020, compared with 46.9% in Q3 2019.
Phase III trials were the second most active with a 19.3% share in Q3 2020, compared with 17.3% in Q3 2019. Phase IV trials held a 17.8% share in Q3 2020, against 19.6% in Q3 2019, followed by Phase I trials with a 15.7% share in Q3 2020, over 16.2% in Q3 2019.
Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.